Halozyme Therapeutics, Inc., a biotechnology company, researches, develops, and commercializes human enzymes and other drug candidates in the United States, Switzerland, and internationally. The company has market cap of $2.57 billion. The companyÂ’s human enzymes are used to facilitate the delivery of injected drugs and fluids, enhancing the efficacy and the convenience of other drugs or can be used to alter tissue structures for clinical benefit. It currently has negative earnings. The Company’s products are based on the Enhanze technology, a patented recombinant human hyaluronidase enzyme that enables the subcutaneous delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.
Among 9 analysts covering Artisan Partners Asset Management Inc (NYSE:APAM), 2 have Buy rating, 2 Sell and 5 Hold. Therefore 22% are positive. Artisan Partners Asset Management Inc has $57 highest and $26 lowest target. $34.75’s average target is -5.18% below currents $36.65 stock price. Artisan Partners Asset Management Inc had 46 analyst reports since July 21, 2015 according to SRatingsIntel. The rating was upgraded by Keefe Bruyette & Woods to “Outperform” on Monday, May 1. The rating was downgraded by Wood to “Market Perform” on Wednesday, August 2. Goldman Sachs downgraded the stock to “Neutral” rating in Tuesday, October 27 report. The rating was maintained by Wood on Friday, October 14 with “Market Perform”. Credit Suisse maintained the stock with “Outperform” rating in Wednesday, November 25 report. On Tuesday, November 14 the stock rating was maintained by Jefferies with “Hold”. The rating was maintained by Jefferies with “Hold” on Monday, September 25. The firm has “Outperform” rating given on Tuesday, October 27 by RBC Capital Markets. The rating was maintained by Keefe Bruyette & Woods with “Hold” on Thursday, December 21. As per Friday, December 15, the company rating was maintained by RBC Capital Markets.
The stock decreased 2.94% or $1.11 during the last trading session, reaching $36.65. About 979,126 shares traded or 151.65% up from the average. Artisan Partners Asset Management Inc. (NYSE:APAM) has declined 8.04% since February 8, 2017 and is downtrending. It has underperformed by 24.74% the S&P500.
Artisan Partners Asset Management Inc. is publicly owned investment manager. The company has market cap of $2.77 billion. It provides its services to pension and profit sharing plans, trusts, endowments, foundations, charitable organizations, government entities, private funds and non-U.S. funds, as well as mutual funds, non-U.S. funds and collective trusts. It has a 19.23 P/E ratio. It manages separate client-focused equity and fixed income portfolios.
Investors sentiment decreased to 1.01 in Q3 2017. Its down 0.49, from 1.5 in 2017Q2. It is negative, as 19 investors sold Artisan Partners Asset Management Inc. shares while 62 reduced holdings. 32 funds opened positions while 50 raised stakes. 47.38 million shares or 3.27% less from 48.99 million shares in 2017Q2 were reported. Moreover, Ameriprise Fincl Inc has 0% invested in Artisan Partners Asset Management Inc. (NYSE:APAM). Ny State Teachers Retirement Sys has 3,900 shares. Geode Capital Lc has 488,935 shares for 0.01% of their portfolio. Wesbanco Bank Incorporated invested in 0.01% or 6,460 shares. Schroder Mngmt Gp accumulated 296,764 shares. Menta Limited Company invested 0.29% in Artisan Partners Asset Management Inc. (NYSE:APAM). The New York-based Morgan Stanley has invested 0% in Artisan Partners Asset Management Inc. (NYSE:APAM). Dimensional Fund Advsrs L P has 0.01% invested in Artisan Partners Asset Management Inc. (NYSE:APAM) for 1.03M shares. Renaissance Ltd Llc reported 0.01% in Artisan Partners Asset Management Inc. (NYSE:APAM). Lucus Advsrs Ltd Limited Liability Company holds 0.49% or 10,701 shares. First Quadrant Lp Ca has invested 0% in Artisan Partners Asset Management Inc. (NYSE:APAM). Acadian Asset Management Ltd Liability reported 0% in Artisan Partners Asset Management Inc. (NYSE:APAM). Comerica Bankshares has invested 0% in Artisan Partners Asset Management Inc. (NYSE:APAM). Glenmede Na holds 0% or 3,830 shares in its portfolio. Virginia Retirement Et Al stated it has 12,400 shares or 0% of all its holdings.
Analysts await Halozyme Therapeutics, Inc. (NASDAQ:HALO) to report earnings on February, 27. They expect $0.67 earnings per share, up 419.05% or $0.88 from last year’s $-0.21 per share. HALO’s profit will be $94.51M for 6.81 P/E if the $0.67 EPS becomes a reality. After $0.02 actual earnings per share reported by Halozyme Therapeutics, Inc. for the previous quarter, Wall Street now forecasts 3,250.00% EPS growth.
Third Security Llc holds 19.28% of its portfolio in Halozyme Therapeutics, Inc. for 17.59 million shares. Senzar Asset Management Llc owns 3.83 million shares or 16.24% of their US portfolio. Moreover, Bb Biotech Ag has 4.15% invested in the company for 8.63 million shares. The Minnesota-based First Light Asset Management Llc has invested 2.45% in the stock. Snyder Capital Management L P, a California-based fund reported 2.47 million shares.
The stock decreased 0.05% or $0.01 during the last trading session, reaching $18.24. About 904,769 shares traded. Halozyme Therapeutics, Inc. (HALO) has risen 44.89% since February 8, 2017 and is uptrending. It has outperformed by 28.19% the S&P500.